Life science commercialization is the work of turning a research finding into a drug, device, diagnostic or tool that reaches patients and earns revenue. In practice that means five decisions made in order: whether the science has a market, how to protect it, whether to license or form a company, how to clear regulators, and how to fund the years in between. Get the order wrong and you spend money on the wrong problem. This guide walks through each decision for university researchers, tech transfer offices and founders working in the United States.
TL;DR
- Commercialization starts well before a product exists: test clinical need, competing products and patient access early, using a structured scorecard.
- Your two main routes are licensing to an existing company or forming a startup. Large pharma rarely licenses before Phase II data, so early assets usually need a startup or a small biotech.
- Regulatory strategy (510(k), PMA, De Novo for devices) shapes your budget and timeline, so decide it before you raise money.
- License terms such as exclusivity, royalties, milestones and equity decide whether investors will fund the company.
- Specialist advisors can shorten the path by covering IP, licensing, grants and investor introductions in one plan.
Table of Contents
- What life science commercialization actually means
- Step 1: Assess commercial potential before you spend on anything
- Step 2: Protect the invention and understand who owns it
- Step 3: Choose your route: license, startup or partnership
- Step 4: Get the license terms right
- Step 5: Map the regulatory pathway early
- Step 6: Form and fund the company
- Step 7: Plan commercial readiness, market access and launch
- Our perspective: commercialization is a sequencing problem
- How we can help
- FAQ
- Sources
What life science commercialization actually means
A discovery is not a product. A product has a defined user, a protected position, a route through regulators, a way to be paid for and a team that can make and deliver it. Commercialization is everything that sits between the publication and that product.
The gap is real and it is financial. Federal support generally stops shortly after basic research discoveries, and industry and private investment have to carry the work from there to healthcare products. That handoff is where most academic projects stall: the lab has data, but nobody has paid for the next experiment that would convince a buyer.
The field you work in changes the shape of the journey. A therapeutic faces long clinical trials. A medical device may move faster but still needs a regulatory pathway. A diagnostic or research tool may reach customers sooner, with reimbursement or adoption as the main hurdle. Engineering and physical-science technologies applied to health often need a partner who understands the clinical setting. The steps below apply to all of them, with different weights.
Step 1: Assess commercial potential before you spend on anything
The cheapest mistake to fix is the one you catch first. Before filing patents or incorporating, put the technology through a structured assessment. A technology readiness self-assessment scorecard from a Canadian translation center is a good example of the format: it scores technology development, patent filing, clinical need, patient population, barriers to reaching patients and competing products.
Turn that into questions you can answer honestly:
- Who has the problem? Name the patient group, the clinician who treats them and the person who pays.
- What do they use today? Competing products and standard of care are your real benchmark, not other research papers.
- What stops patients from getting it? Reimbursement, workflow changes, surgeon training, cold-chain logistics or a long approval path can each sink a good technology.
- How far along is the technology? Proof of concept in a cell line is a different asset from animal efficacy data or a working prototype.
- Can it be protected? Check whether a patent position is realistic and who owns the invention.
An assessment does not need to be a verdict. Its job is to tell you what evidence is missing and what it would cost to get it. That list becomes your development plan and, later, your pitch.
Step 2: Protect the invention and understand who owns it
In university research, ownership is usually settled by employment agreements and funding terms, not by who had the idea. Disclose the invention to your technology transfer office before you publish or present, because early public disclosure can damage patent rights. Your office then decides whether to file, and on what terms to license.
Patent strategy is more than filing. It means deciding which claims matter commercially, which countries are worth the cost, and how the portfolio looks to an investor doing diligence. A narrow patent on a method nobody will use is worth little. A well-structured filing around the product a buyer would actually sell can anchor a company. This is where early advice pays for itself, and where legal work needs to be done by registered patent counsel.
Step 3: Choose your route: license, startup or partnership
The right route depends on the stage of the asset and who is likely to carry it forward.
| Route | Best when | What to expect |
|---|---|---|
| License to an established company | The technology is close to a product and a company already sells in the space | Faster handoff, the licensee funds development, you receive royalties and milestones |
| License to a startup (spinout) | The asset is early and no large company will take it yet | A new company funded by investors or grants, with equity and founder roles to settle |
| Sponsored research or collaboration | A company wants access to your lab or data before committing | Shared funding, clear rules on who owns new results |
| Public-private partnership | The work serves a broad regulatory or public-health need | The FDA works with government, academic, scientific, patient and industry organizations through such partnerships and research collaboration agreements |
Why early assets usually need a startup
Large pharmaceutical companies generally do not consider licensing until a drug has passed Phase II trials, and faculty entrepreneurs or small companies typically raise money for the earlier trials. A more recent perspective makes the same point: big pharma typically no longer licenses early-stage technologies directly, while licenses to startups and small and mid-sized biotech firms are increasing.
If your technology is preclinical, plan on a company, not a quick license to a major. That changes what you need: a founding team, a license from the university, a capital plan and a development roadmap.
Step 4: Get the license terms right
The university license is the legal foundation of a spinout. Terms can include exclusivity, royalties, milestone payments, maintenance fees and equity, and institutions may require the company to diligently develop the technology. Each term affects fundraising:
- Exclusivity matters because investors rarely fund a product the company cannot protect.
- Royalty stacking and heavy upfront fees can make a company hard to finance.
- Milestones and diligence obligations need to match a realistic development timeline, or the license is at risk when the science takes longer than planned.
- Equity gives the university a stake and should be set so founders and investors still have workable ownership.
Standard templates can cut negotiation time. Startup-friendly license templates and term sheets such as US-BOLT are meant to reduce negotiation time and cost for academic institutions and early-stage entrepreneurs. The creators of the US-BOLT term sheet hope standardized terms will help therapeutics, diagnostics and medical devices reach the market earlier.
Step 5: Map the regulatory pathway early
Regulation is not a late-stage chore. It determines what data you must generate, how long it takes and how much capital you need. For drugs and biologics, the path runs through FDA-regulated clinical development, so it helps to talk to regulatory specialists before designing the first animal study.
For medical devices in the US, the pathway follows risk. PMA applies to most Class III devices, 510(k) to some Class II devices, and De Novo to devices not comparable enough to marketed ones. The same source notes that an Investigational Device Exemption (IDE) permits an investigational device to be studied to collect safety or effectiveness data, and that early feasibility studies can help refine device design and development.
What this means for planning:
- Classify your product early. Class and intended use drive the route.
- Find a predicate, or learn that you do not have one. A comparable marketed device points toward 510(k); its absence may point to De Novo.
- Budget the evidence. A PMA route needs far more clinical data than a 510(k), and your fundraising target should reflect that.
- Use the FDA's own pre-submission channels and your regulatory consultant to confirm your assumptions before you commit to a plan.
Step 6: Form and fund the company
Forming a life science startup from university research follows a recognizable sequence:
- Disclose and secure rights. Complete invention disclosure and agree license terms with the university.
- Assemble the team. The inventor is rarely the right full-time CEO, and investors look for operating experience alongside the science.
- Incorporate and capitalize. Set up the entity, founder equity and the university's stake.
- Write the development plan. A short roadmap showing which milestones each funding round buys.
- Raise non-dilutive money first where you can. Federal programs such as SBIR and STTR grants fund small-business research and can pay for the proof-of-concept work that makes the company investable without giving up equity.
- Approach investors with evidence. Show clinical need, a protected position, a regulatory route and a credible team.
Sequencing matters. Grants can buy the data that raises the valuation of the first priced round, and a clean license and cap table remove objections in diligence. Investors also respond to introductions through people they trust more than cold outreach, so a warm path to relevant angels, venture funds and strategic partners is worth planning early.
Step 7: Plan commercial readiness, market access and launch
The most common blind spot among research teams is treating commercial planning as something that starts after approval. Launch problems usually trace back to decisions made years before.
Build a readiness checklist while you are still in development:
- Evidence the buyer cares about. Clinical endpoints are for regulators; payers and hospital committees ask about outcomes and cost.
- Reimbursement and access. Know who pays, under which code or contract, and what evidence they require.
- Manufacturing and supply. Can you make it consistently, at scale and at a workable cost of goods?
- Commercial model. Decide whether to build a sales force, partner with an established company or be acquired. Many small companies partner at this stage because it avoids the cost of building a commercial team.
- Traction signals. Pilot sites, letters of intent, advisory-board input and early customer conversations all show a buyer or investor that demand exists.
This is also where a partnership can return. A startup that has funded its way to meaningful data is the kind of asset a larger company will consider licensing or acquiring.
Our perspective: commercialization is a sequencing problem
We see the same pattern across university labs and early companies: the science is rarely what fails. The order of decisions is.
Teams file patents before asking whether anyone will pay for the product. They form a company before settling license terms that investors can live with. They raise a seed round before they know which regulatory path they are on. Each mistake is fixable, but each one costs months and credibility.
Our team has worked from inside major university technology transfer offices, in startup leadership, in federal grant review and in industry commercialization. That mix matters, because every party in a deal has a different view of the same technology, and the best outcomes come from understanding all of them. We build the plan around the technology in front of us: market assessment first, then IP and licensing strategy, then spinout formation, funding strategy including SBIR and STTR, and finally the introductions to investors and industry partners who can carry it forward.
We also believe legal work should be tightly coordinated with strategy. That is why we work with a dedicated IP law partner, so patent decisions and business decisions are made together instead of in separate conversations.
the author
How we can help
If you hold a life science, biopharma or medical device technology and want a clear plan from assessment to launch, our team supports universities, researchers and founders with IP and patent strategy, licensing structure, spinout formation, funding strategy and investor introductions. Engagements are scoped to your technology and stage.
See the full list of commercialization and licensing services, or start from our home page to tell us about your technology.
FAQ
How long does life science commercialization take?
It depends on the product type and regulatory route. Devices on a 510(k) path generally need less clinical evidence than drugs or PMA devices, and drug development involves multiple clinical phases. Plan on a multi-year program and set funding milestones that cover each stage rather than one distant finish line.
Should researchers license their invention or start a company?
It depends on how mature the technology is. Because large pharmaceutical companies generally wait until Phase II to license a drug, early-stage assets often need a startup or a small biotech to carry them. Closer-to-market technologies can often be licensed directly to an established company.
What does a university license usually include?
Typical terms include exclusivity, royalties, milestone payments, maintenance fees and equity, plus an obligation to develop the technology diligently. These terms should be negotiated with your funding plan in mind. Standardized templates such as US-BOLT aim to speed that negotiation for early-stage companies.
Which FDA pathway applies to a medical device?
The pathway follows risk and novelty. Most Class III devices go through PMA, some Class II devices use 510(k), and De Novo covers devices that are not comparable enough to marketed devices. Confirm your classification with a regulatory specialist and the FDA before you plan your evidence budget.
When should I start commercial planning?
As soon as the science shows promise, and well before approval. Early work on clinical need, competing products, patient access and reimbursement tells you what data to generate and prevents costly redirections later.
Sources
- Technology Readiness Assessment self-assessment scorecard
- Moving Research to Patient Applications through Technology Transfer
- Biotechnology Entrepreneurship, chapter on technology transfer (NIH OTT, 2020)
- AUTM US-BOLT early-stage life science term sheet
- FDA: Technology Transfer and Public-Private Partnerships
- NIH SEED: Drug Regulatory Case Study